AGTR1 and Parkinson disease: Osmotic minipump infusions of AT1 receptor autoantibodies disrupt BBB and affect the brain, leading to upregulation of the pro-inflammatory RAS activity in the SN and a significant increase in dopaminergic neurodegeneration in two different rat PD models [81].